Amgen (CHIX:AMGD) 6-Month Price Index: 1.17 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AMGD Amgen Inc CHIX:AMGD
89 GF Score
Price €285.00
GF Value €326.10
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Amgen 6-Month Price Index?

Amgen CHIX:AMGD 89 6-Month Price Index is 1.17 as of Jul. 20, 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 89/100 and a GF Value™ of €326.10 (Modestly Undervalued). The stock has 8 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-07-20), Amgen's 6-Month Price Index is 1.17.

Amgen  (CHIX:AMGd) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Amgen 6-Month Price Index Related Terms

CHIX:AMGD vs GILD, PFE, BMY: 6-Month Price Index Comparison

For the Drug Manufacturers - General subindustry, Amgen's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CHIX:AMGD
89GF Score
Amgen Inc CHIX:AMGD
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen  (CHIX:AMGd) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.17 mean?
Amgen (CHIX:AMGD) has a 6-Month Price Index of 1.17 as of Jul. 20, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Amgen and its competitors.
Is Amgen's 6-Month Price Index too high?
Amgen's current 6-Month Price Index is 1.17. Overall, Amgen has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's 6-Month Price Index compare to GILD and PFE?
Amgen's 6-Month Price Index of 1.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Amgen and its competitors. Amgen's current 6-Month Price Index is 1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €326.10, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current 6-Month Price Index is 1.17. Amgen's overall GF Score™ is 89/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current 6-Month Price Index is 1.17 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (CHIX:AMGD) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be undervalued. The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €326.10. GuruFocus considers Amgen to be Modestly Undervalued.

Key valuation signals for CHIX:AMGD:

  • 6-Month Price Index: 1.17
  • GF Value™: €326.10 vs. price of €285.00 (12.6% below fair value)
  • GF Score™: 89/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
89GF Score

Get the complete analysis for CHIX:AMGD

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€285.00
Price
€326.10
GF Value